Effect of pulmonary exacerbations treated with oral antibiotics on clinical outcomes in cystic fibrosis

Thorax

Volumn 72, Issue 4, 2017, Pages 327-332

  Stanojevic, Sanja ^a   McDonald, Alexandra ^a   Waters, Valerie ^b   Macdonald, Sarah ^a   Horton, Eric ^a   Tullis, Elizabeth ^c,d   Ratjen, Felix ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c ST MICHAEL'S HOSPITAL   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

Author keywords

Cystic Fibrosis; Respiratory Infection; Respiratory Measurement

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; BODY MASS; CHILD; COHORT ANALYSIS; CYSTIC FIBROSIS; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; NUTRITIONAL STATUS; OUTCOME ASSESSMENT; RETROSPECTIVE STUDY; SCHOOL CHILD; TREATMENT RESPONSE; DISEASE COURSE; INTRAVENOUS DRUG ADMINISTRATION; LUNG FUNCTION TEST; MICROBIOLOGY; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; CHILD; CYSTIC FIBROSIS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; NUTRITIONAL STATUS; RESPIRATORY FUNCTION TESTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84983504564     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2016-208450     Document Type: Article

References (22)

1. Ellaffi M, Vinsonneau C, Coste J, et al. One-year outcome after severe pulmonary exacerbation in adults with cystic fibrosis. Am J Respir Crit Care Med 2005;171:158-64.
2. Goss CH, Burns JL. Exacerbations in cystic fibrosis. 1: epidemiology and pathogenesis. Thorax 2007;62:360-7.
3. de Boer K, Vandemheen KL, Tullis E, et al. Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis. Thorax 2011;66:680-5.
4. Konstan MW, Morgan WJ, Butler SM, et al. Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis. J Pediatr 2007;151:134-9, 9.e1.
5. Sanders DB, Bittner RC, Rosenfeld M, et al. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010;182:627-32.
6. Waters V, Atenafu EG, Salazar JG, et al. Chronic Stenotrophomonas maltophilia infection and exacerbation outcomes in cystic fibrosis. J Cyst Fibros 2012;11:8-13.
7. Waters V, Stanojevic S, Atenafu EG, et al. Effect of pulmonary exacerbations on long-Term lung function decline in cystic fibrosis. Eur Respir J 2012;40:61-6.
8. Wagener JS, Rasouliyan L, VanDevanter DR, et al. Oral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol 2013;48:666-73.
9. Kerem E, Reisman J, Corey M, et al. Prediction of mortality in patients with cystic fibrosis. N Engl J Med 1992;326:1187-91.
10. Farrell PM, Rosenstein BJ, White TB, et al. Guidelines for diagnosis of cystic fibrosis in newborns through older adults: cystic Fibrosis Foundation consensus report. J Pediatr 2008;153:S4-14.
11. Waters V, Yau Y, Prasad S, et al. Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease. Am J Respir Crit Care Med 2011;183:635-40.
12. Waters V, Stanojevic S, Klingel M, et al. Prolongation of antibiotic treatment for cystic fibrosis pulmonary exacerbations. J Cyst Fibros 2015;14:770-6.
13. Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: The global lung function 2012 equations. Eur Respir J 2012;40:1324-43.
14. Kuczmarski RJ, Ogden CL, Guo SS, et al. 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat 11 2002;246:1-190.
15. Lee TW, Brownlee KG, Conway SP, et al. Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients. J Cyst Fibros 2003;2:29-34.
16. Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group. N Engl J Med 1994;331:637-42.
17. Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-Term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006;354:229-40.
18. Anstead M, Saiman L, Mayer-Hamblett N, et al. Pulmonary exacerbations in CF patients with early lung disease. J Cyst Fibros 2014;13:74-9.
19. Ratjen F, Saiman L, Mayer-Hamblett N, et al. Effect of azithromycin on systemic markers of inflammation in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa. Chest 2012;142:1259-66.
20. Assael BM, Pressler T, Bilton D, et al. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: A comparative efficacy trial. J Cyst Fibros 2013;12:130-40.
21. Konstan MW, Flume PA, Kappler M, et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. J Cyst Fibros 2011;10:54-61.
22. Stuart Elborn J, Geller DE, Conrad D, et al. A phase 3, open-label, randomized trial to evaluate the safety and efficacy of levofloxacin inhalation solution (APT-1026) versus tobramycin inhalation solution in stable cystic fibrosis patients. J Cyst Fibros 2015;14:507-14.